Glucagon-Like Peptide 1-Based Therapies: Panacea or Cautionary Tale?

Abstract

Get full access to this article

View all access options for this article.

References

Drucker

DJ.

Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47(11):1873-1888. doi:10.2337/dci24-0003

Peiper

Vanzhula

Levinson

CA.

Are recent decreases in adult obesity trends in the United States encouraging or alarming?

Prev Med. 2025;196:108297. doi:10.1016/j.ypmed.2025.108297

US Food & Drug Administration. FDA approves treatment for serious liver disease known as ‘MASH.’ August 15, 2025. Accessed August 28, 2025. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash

Merative. RED BOOK. https://www.merative.com/documents/micromedex-red-book

Eli Lilly and Company. Zepbound pricing information. Accessed August 24, 2025. https://pricinginfo.lilly.com/zepbound

Military.com. Pentagon drops coverage of GLP-1 weight loss meds for Medicare-eligible retirees. August 19, 2025. Accessed October 21, 2025. https://www.military.com/daily-news/2025/08/19/pentagon-drops-coverage-of-glp-1-weight-loss-meds-medicare-eligible-retirees.html

McPhillips

. Major insurance changes are coming to GLP-1 drugs for weight loss. CNN. July 1, 2025. Accessed October 21, 2025. https://www.cnn.com/2025/07/01/health/zepbound-wegovy-insurance-cvs-bcbs-weight-loss

Dynamic Wellness Solutions. Managing GLP-1 class drugs with a dietitian: a comprehensive guide. December 15 , 2024. Accessed August 24, 2025. https://dwsolutionsusa.com/managing-glp-1-class-drugs-with-a-dietitian-a-comprehensive-guide/

Chang

Vaduganathan

Plutzky

Aroda

VR.

Bridging the gap for patients with diabetes and cardiovascular disease through cardiometabolic collaboration. Curr Diab Rep. 2019;19(12):157. doi:10.1007/s11892-019-1260-0

10.

Isaacs

Kruger

Spollett

GR.

Optimizing therapeutic outcomes with oral semaglutide: a patient-centered approach. Diabetes Spectr. 2021;34(1):7-19. doi:10.2337/ds20-0016

11.

Neeland

Linge

Birkenfeld

AL.

Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(suppl 4):16-27. doi:10.1111/dom.15728

12.

Mozaffarian

Agarwal

Aggarwal

, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33(8):1475-1503. doi:10.1002/oby.24336

13.

Gleason

Urick

Marshall

Friedlander

Qiu

Leslie

RS.

Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. J Manag Care Spec Pharm. 2024;30(8):860-867. doi:10.18553/jmcp.2024.23332

14.

Palanca

Ampudia-Blasco

Calderón

, et al. Real-world evaluation of GLP-1 receptor agonist therapy persistence, adherence and therapeutic inertia among obese adults with type 2 diabetes. Diabetes Ther. 2023;14(4):723-736. doi:10.1007/s13300-023-01382-9